




NewLink Genetics Corporation
Investor Relations Department
2503 South Loop Drive
Ames, IA 50010
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

Company Profile

Founded in 1999, NewLink Genetics is an immuno-oncology company focused on discovering and developing novel products for the treatment of cancer. The drug discovery and development teams at NewLink Genetics are relentlessly pursuing a wide range of immuno-oncology portfolio candidates with the potential to change the oncology landscape. NewLink Genetics' portfolio includes two small-molecule product candidates currently in clinical development. These product candidates inhibit the IDO pathway, a key immuno-oncology target, and focus on breaking the immune system's tolerance to cancer.

Press Releases [\[View all \]](#)

Sep 7, 2017
[Updated Data for Indoximod Plus KEYTRUDA® \(pembrolizumab\) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma](#)

Aug 29, 2017
[NewLink Genetics to Participate in Upcoming Investor Conferences](#)

Jul 28, 2017
[NewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program](#)

Jul 27, 2017
[NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802](#)

Jul 10, 2017
[NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 6, 2017
[Annual Report \(10-K\)](#)

Mar 31, 2017
[Proxy Statement \(DEF 14A\)](#)

Aug 3, 2017
[Quarterly Report \(10-Q\)](#)

May 5, 2017
[Quarterly Report \(10-Q\)](#)

Nov 8, 2016
[Quarterly Report \(10-Q\)](#)